Oncology/Genetcis| Volume 165, ISSUE 3, P657-663, March 2019

Download started.


Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection

Published:October 27, 2018DOI:


      The incidence, clinical characteristics, and long-term outcomes of patients with gastroenteropancreatic neuroendrocrine tumors and carcinoid syndrome undergoing operative resection have not been well characterized.


      Patients undergoing resection of primary or metastatic gastroenteropancreatic neuroendrocrine tumors between 2000 and 2016 were identified from an 8-institution collaborative database. Clinicopathologic and postoperative characteristics as well as overall survival and disease-free survival were compared among patients with and without carcinoid syndrome.


      Among 2,182 patients who underwent resection, 139 (6.4%) had preoperative carcinoid syndrome. Patients with carcinoid syndrome were more likely to have midgut primary tumors (44.6% vs 21.4%, P < .001), lymph node metastasis (63.4% vs 44.3%, P < .001), and metastatic disease (62.8% vs 26.7%, P < .001). There was no difference in tumor differentiation, grade, or Ki67 status. Perioperative carcinoid crisis was rare (1.6% vs 0%, P < .01), and the presence of preoperative carcinoid syndrome was not associated with postoperative morbidity (38.8% vs 45.5%, P = .129). Substantial symptom improvement was reported in 59.5% of patients who underwent curative-intent resection, but occurred in only 22.7% who underwent debulking. Despite an association on univariate analysis (P = .04), carcinoid syndrome was not independently associated with disease-free survival after controlling for confounding factors (hazard ratio 0.97, 95% confidence interval 0.641.45). Preoperative carcinoid syndrome was not associated with overall survival on univariate or multivariate analysis.


      Among patients undergoing operative resection of gastroenteropancreatic neuroendrocrine tumors, the prevalence of preoperative carcinoid syndrome was low. Although operative intervention with resection or especially debulking in patients with carcinoid syndrome was disappointing and often failed to improve symptoms, after controlling for markers of tumor burden, carcinoid syndrome was not independently associated with worse disease-free survival or overall survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dasari A.
        • Shen C.
        • Halperin D.
        • et al.
        Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.
        JAMA Oncol. 2017; 3: 1335-1342
        • Halperin D.M.
        • Shen C.
        • Dasari A.
        • et al.
        Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
        Lancet Oncol. 2017; 18: 525-534
        • Cai B.
        • Broder M.S.
        • Chang E.
        • et al.
        Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
        World J Gastroenterol. 2017; 23: 7283-7291
        • Ito T.
        • Igarashi H.
        • Nakamura K.
        • et al.
        Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
        J Gastroenterol. 2015; 50: 58-64
        • Soga J.
        Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases.
        J Exp Clin Cancer Res. 2003; 22: 517-530
        • Modlin I.M.
        • Oberg K.
        • Chung D.C.
        • et al.
        Gastroenteropancreatic neuroendocrine tumours.
        Lancet Oncol. 2008; 9: 61-72
        • Janson E.T.
        • Holmberg L.
        • Stridsberg M.
        • et al.
        Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center.
        Ann Oncol. 1997; 8: 685-690
        • Jann H.
        • Roll S.
        • Couvelard A.
        • et al.
        Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.
        Cancer. 2011; 117: 3332-3341
        • Formica V.
        • Wotherspoon A.
        • Cunningham D.
        • et al.
        The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
        Br J Cancer. 2007; 96: 1178-1182
        • Zandee W.T.
        • de Herder W.W.
        • Jann H.
        Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?.
        Lancet Oncol. 2017; 18: e299
        • Ducreux M.
        Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?.
        Lancet Oncol. 2017; 18: 426-428
        • Soga J.
        • Yakuwa Y.
        • Osaka M.
        Carcinoid syndrome: a statistical evaluation of 748 reported cases.
        J Exp Clin Cancer Res. 1999; 18: 133-141
        • Babyak M.A.
        What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models.
        Psychosom Med. 2004; 66: 411-421
        • Onaitis M.W.
        • Kirshbom P.M.
        • Hayward T.Z.
        • et al.
        Gastrointestinal carcinoids: characterization by site of origin and hormone production.
        Ann Surg. 2000; 232: 549-556
        • Ito T.
        • Lee L.
        • Jensen R.T.
        Carcinoid-syndrome: recent advances, current status and controversies.
        Curr Opin Endocrinol Diabetes Obes. 2018; 25: 22-35
        • Kirshbom P.M.
        • Kherani A.R.
        • Onaitis M.W.
        • et al.
        Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids.
        Surgery. 1998; 124: 1063-1070
        • Alexandraki K.
        • Angelousi A.
        • Boutzios G.
        • et al.
        Management of neuroendocrine tumors of unknown primary.
        Rev Endocr Metab Disord. 2017;
        • Liang P.S.
        • Shaffer K.
        Metastatic gastrointestinal carcinoid tumor with unknown primary site.
        Radiol Case Rep. 2007; 2: 90
        • Bartlett E.K.
        • Roses R.E.
        • Gupta M.
        • et al.
        Surgery for metastatic neuroendocrine tumors with occult primaries.
        J Surg Res. 2013; 184: 221-227
        • La Rosa S.
        • Franzi F.
        • Albarello L.
        • et al.
        Serotonin-producing enterochromaffin cell tumors of the pancreas: clinicopathologic study of 15 cases and comparison with intestinal enterochromaffin cell tumors.
        Pancreas. 2011; 40: 883-895
        • Zavras N.
        • Schizas D.
        • Machairas N.
        • et al.
        Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review.
        Oncol Lett. 2017; 13: 2373-2376
        • Feldman J.M.
        • Jones R.S.
        Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis.
        Ann Surg. 1982; 196: 33-37
        • Riechelmann R.P.
        • Pereira A.A.
        • Rego J.F.
        • et al.
        Refractory carcinoid syndrome: a review of treatment options.
        Ther Adv Med Oncol. 2017; 9: 127-137
        • Massimino K.
        • Harrskog O.
        • Pommier S.
        • et al.
        Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
        J Surg Oncol. 2013; 107: 842-846
        • Woltering E.A.
        • Wright A.E.
        • Stevens M.A.
        • et al.
        Development of effective prophylaxis against intraoperative carcinoid crisis.
        J Clin Anesth. 2016; 32: 189-193
        • Kinney M.A.
        • Warner M.E.
        • Nagorney D.M.
        • et al.
        Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.
        Br J Anaesth. 2001; 87: 447-452